# SPORE in Ovarian Cancer

> **NIH NIH P50** · JOHNS HOPKINS UNIVERSITY · 2024 · $2,496,726

## Abstract

SUMMARY - OVERALL
Ovarian cancer is one of the most aggressive cancers in the United States and a major cause of cancer morbidity
and mortality. This Johns Hopkins-University of Pennsylvania Ovarian Cancer SPORE application focuses on
reducing ovarian cancer incidence and mortality by translating new laboratory-based discoveries into
improvements in ovarian cancer diagnosis and treatment. This highly translational program contains three
hypothesis-driven Research Projects, three Core Resources, the Career Enhancement Program (CEP), and the
Developmental Research Program (DRP). The objective of Project 1 is to develop a novel brush-based
approach to sample fallopian tubes and ovaries for precursor lesions and to define the molecular attributes of
detected precursors for proper clinical management. The goal of Project 2 and Project 3 is to provide critical
preclinical and early clinical data for developing more effective combined therapy to treat advanced ovarian
cancer, especially for recurrent diseases. Specifically, Project 2 will evaluate cyclin E1 protein as a biomarker
of ovarian cancers responsive to a new WEE1 inhibitor. Resistance will be addressed with combination WEE1
and ATR inhibition and underlying mechanism of response and resistance will be defined by treatment-related
proteins identified at stressed replication forks. Project 3 will exploit a DNA repair vulnerability in ARID1A mutant
ovarian cancers. Specifically, the clinical efficacy of the combination of temozolomide and the PARP inhibitor,
senaparib, will be evaluated in a Phase II trial. All the three new projects originate from the current CEP/DPR
projects. These Projects are supported by an Administrative Core, a Biorepository/Pathology Core, and a
Computation/Biostatistics Core. Finally, the CEP and DRP comprise pipelines of human capital and innovative
ideas, respectively, which will fuel future SPORE advances. This application is strongly supported by institutional
commitment to ensure its success.

## Key facts

- **NIH application ID:** 10935404
- **Project number:** 2P50CA228991-06A1
- **Recipient organization:** JOHNS HOPKINS UNIVERSITY
- **Principal Investigator:** Ronny I DRAPKIN
- **Activity code:** P50 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $2,496,726
- **Award type:** 2
- **Project period:** 2018-09-18 → 2029-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10935404

## Citation

> US National Institutes of Health, RePORTER application 10935404, SPORE in Ovarian Cancer (2P50CA228991-06A1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10935404. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*